» Articles » PMID: 34739968

De Novo Design of Novel Protease Inhibitor Candidates in the Treatment of SARS-CoV-2 Using Deep Learning, Docking, and Molecular Dynamic Simulations

Overview
Journal Comput Biol Med
Publisher Elsevier
Date 2021 Nov 5
PMID 34739968
Citations 28
Authors
Affiliations
Soon will be listed here.
Abstract

The main protease of SARS-CoV-2 is a critical target for the design and development of antiviral drugs. 2.5 M compounds were used in this study to train an LSTM generative network via transfer learning in order to identify the four best candidates capable of inhibiting the main proteases in SARS-CoV-2. The network was fine-tuned over ten generations, with each generation resulting in higher binding affinity scores. The binding affinities and interactions between the selected candidates and the SARS-CoV-2 main protease are predicted using a molecular docking simulation using AutoDock Vina. The compounds selected have a strong interaction with the key MET 165 and Cys145 residues. Molecular dynamics (MD) simulations were run for 150ns to validate the docking results on the top four ligands. Additionally, root-mean-square deviation (RMSD), root-mean-square fluctuation (RMSF), and hydrogen bond analysis strongly support these findings. Furthermore, the MM-PBSA free energy calculations revealed that these chemical molecules have stable and favorable energies, resulting in a strong binding with Mpro's binding site. This study's extensive computational and statistical analyses indicate that the selected candidates may be used as potential inhibitors against the SARS-CoV-2 in-silico environment. However, additional in-vitro, in-vivo, and clinical trials are required to demonstrate their true efficacy.

Citing Articles

Molecular Docking Studies and In Vitro Activity of Pancreatic Lipase Inhibitors from Yak Milk Cheese.

Wang P, Song X, Liang Q Int J Mol Sci. 2025; 26(2).

PMID: 39859469 PMC: 11771213. DOI: 10.3390/ijms26020756.


An integrative analysis reveals cancer risk associated with artificial sweeteners.

Xie J, Zhu Y, Yang Z, Yu Z, Yang M, Wang Q J Transl Med. 2025; 23(1):32.

PMID: 39780215 PMC: 11708064. DOI: 10.1186/s12967-024-06047-0.


Computational design of CDK1 inhibitors with enhanced target affinity and drug-likeness using deep-learning framework.

Lu Z, Han J, Ji Y, Li B, Zhang A Heliyon. 2025; 10(22):e40345.

PMID: 39748968 PMC: 11693894. DOI: 10.1016/j.heliyon.2024.e40345.


Molecular exploration of natural and synthetic compounds databases for promising hypoxia inducible factor (HIF) Prolyl-4- hydroxylase domain (PHD) inhibitors using molecular simulation and free energy calculations.

Sayaf A, Kousar K, Suleman M, Albekairi N, Alshammari A, Mohammad A BMC Chem. 2024; 18(1):236.

PMID: 39593151 PMC: 11590322. DOI: 10.1186/s13065-024-01347-4.


Design, synthesis, biological evaluation and computational studies of 4-Aminopiperidine-3, 4-dihyroquinazoline-2-uracil derivatives as promising antidiabetic agents.

Baziar L, Emami L, Rezaei Z, Solhjoo A, Sakhteman A, Khabnadideh S Sci Rep. 2024; 14(1):26538.

PMID: 39489787 PMC: 11532418. DOI: 10.1038/s41598-024-77481-9.